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Abstract
Background Bibrocathol is a well-established antiseptic
drug for the treatment of acute eyelid diseases like blephar-
itis. Despite its frequent use in clinical practice, no con-
trolled clinical trial on the efficacy of bibrocathol 2% eye
ointment has been performed until now. The aim of the
study was to investigate efficacy, safety and tolerability of
bibrocathol (Posiformin® 2 %) eye ointment in patients
diagnosed with blepharitis.
Methods In this multi-center, randomized, double-masked,
placebo-controlled parallel-group comparison, the change of
signs and symptoms (sum score) of blepharitis in 197 patients
(ITT (intention-to-treat-group); mean age 56±18 years, 56 %
female, active drug:vehicle097:100) over 2 weeks treatment
with bibrocathol 2 % eye ointment was evaluated.
Results Patients receiving bibrocathol 2 % showed greater
improvement in the sum score than the placebo patients (p<
0.0001, Cohen’s effect size d00.73). Also, the results from
further efficacy assessments improvement of single symp-
toms and ocular discomfort measured by a VAS (visual
analogue scale) supported treatment with bibrocathol.
Patients and investigators provided favorable tolerability
ratings preferring bibrocathol over placebo. No safety issues
were observed with regard to intraocular pressure, visual
acuity, or occurrence of adverse events.
Conclusions Blepharitis therapy with the antiseptic bibro-
cathol 2 % in this trial was highly efficacious and safe.
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Introduction
Inflammation of the palpebra and the edge of the palpebra
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ophthalmologist [1, 2]. Predominant symptoms are burning,
itching, and foreign-body sensation with swollen, hyper-
emic eyelids and debris.
Staphylococcal blepharitis, seborrheic blepharitis, and
mixed forms are summarized as anterior blepharitis in
contrary to posterior blepharitis, which is caused by a
dysfunction of the Meibomian glands. Altered composition
of secretions is frequently associated with specific clinical
abnormalities such as evaporative dry eyes [2, 3].
Standard treatment of blepharitis is lid hygiene. Accord-
ing to the guidelines of the Professional Society of
German Ophthalmologists and the German Ophthalmo-
logic Association, lid hygiene should be supplemented
by antibiotics or antiseptics, depending on disease cause
and related findings [4, 5]. Topical antibiotics may be
administered in case of severe infection, with additional
topical steroids or steroid-antibiotic combination prepa-
rations if necessary [4–6].
Bibrocathol (International non-proprietary name (INN)
4,5,6,7-Tetrabromo-1,3,2-benzodioxabismol-2-ol) is a
topical antiseptic frequently used for the treatment of
blepharitis. Eye ointments containing 2 or 5 % bibroca-
thol and the excipients liquid paraffin, white soft paraf-
fin, and lanolin have been marketed since 1967 for the
treatment of eye irritation, chronic blepharitis, and unin-
fected corneal injuries. Reports of clinical experience
with bibrocathol for inflammation of the edge of the
palpebra exist since the beginning of the 20th century
[7]. Until recently, no controlled, randomized clinical
studies according to the guidelines for Good Clinical
Practice for Trials on Medical Products for Human Use
(GCP) as defined by the International Conference on
Harmonisation (ICH) have been performed with bibro-
cathol 2 % ointment, as these were not required for
marketing authorization in the 1960s. A first double-
blind, prospective, controlled, GCP-compliant clinical
study was recently performed to assess the efficacy of
bibrocathol 5 % (Noviform®) in acute blepharitis [8]. It
demonstrated superior efficacy of bibrocathol 5 % oint-
ment as compared to an ointment vehicle (placebo) after
2 weeks of treatment as assessed by a combined mea-
sure of slit-lamp examination results and patients’ sub-
jective complaints. However, the effect size in this study
was small. Currently, only the 2 % bibrocathol eye
ointment is available on the market (Posiformin® 2 %);
however, no data from a modern clinical trial according
to the standards of ICH-GCP exist to demonstrate its
efficacy and tolerability.
This controlled multicenter clinical trial was per-
formed to evaluate the efficacy and safety of bibrocathol
2 % eye ointment in the treatment of patients with acute
blepharitis.
Materials and methods
As all four participating trial sites were located in the
Ukraine, this trial was approved by the Central Ethics Com-
mittee of Kyiv. It was conducted according to the guidelines
for ICH - GCP and the Declaration of Helsinki, Tokyo 2004,
as well as being in compliance with national Ukrainian law
and regulations.
All patients provided written informed consent to volun-
tarily participate in the trial and to their personal data being
inspected by employees of the sponsor, sponsor’s represen-
tatives, or authorities.
The study was designed as a multi-center, randomized,
double-masked, placebo-controlled parallel-group trial eval-
uating the effects of bibrocathol 2 % eye ointment on acute
blepharitis. Patients were randomly assigned in a 1:1 ratio to
receive either bibrocathol 2 % or vehicle (placebo). The
allocation schedule was generated by the Biometrics Depart-
ment of ReSearch Pharmaceutical Services’ coding system
and contained blocks of six randomization numbers—three
assigned to each treatment arm in random order. Investigators
were not aware of the block size used. The total treatment
period was 14 (± 2) days with four visits at the investigational
site (screening visit [V1], baseline visit on day 1 [V2], control
visit [V3] on day 7±1 and final visit [V4] at day 14±2). A
length of 5 mm bibrocathol 2 % or corresponding vehicle was
applied to both the upper and lower eyelids up to the eyelid
margin with a clean fingertip three times daily (morning,
noon, and evening), after eyelid hygiene, starting on day 1
(V2). All patients were trained to apply the same measures of
lid hygiene (washing the face and cleaning the lid with a
cotton bud according to standards of each study center). Eye
cosmetics and eyelid massage as well as wearing contact
lenses were prohibited.
The identities of the treatments were concealed by study
drugs that were identical in packaging, labeling, size, and
appearance of tubes as well as the schedule of administra-
tion. Since active treatment and vehicle differed in color, the
study medication was distributed to the patients by qualified
site personnel not involved in the measurement of any trial
efficacy or safety parameters. These personnel were
instructed not to reveal the identity of the trial medication
to the investigator or study monitors.
Male and female patients aged≥18 years with signs
and symptoms of moderate blepharitis (sum score of at
least 15 out of 26 points) in ambulatory treatment were
considered for participation. This sum score using a
distinct grading of symptoms was developed in a previ-
ous study [6] and combined both the physicians’ eval-
uation of the four signs and symptoms of blepharitis
severity (lid edema, lid erythema, debris and pouting of
Meibomian glands, with a maximum of 16 points) and
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the patients’ subjective discomfort rating using a visual
analogue scale (VAS) (maximum of 10 points).
Patients were excluded from the study if they suffered
from blepharitis requiring antibiotic treatment or therapy-
resistant blepharitis, had an abnormal eyelid anatomy (other
than due to blepharitis), ocular surgery within the last
90 days, severe dry eye syndrome, an allergic eye disease,
known hypersensitivity to the trial drug or any of the ingre-
dients, severe systemic disease, rheumatoid arthritis or spon-
dylitis, or a history of malignancies of any organ system
within the last 5 years. The following concomitant medica-
tions led to exclusion from the trial: oral or topical anti-
biotics, topical ocular or systemic corticosteroids (except
chronic use of inhaled corticosteroids on stable dose), top-
ical ocular or systemic NSAIDs (except oral acetyl salicylic
acid and occasional use of painkillers) administered 1 month
prior to and during the trial, any other ocular antiseptics
administered during the trial, local ocular use of antihist-
amines, and any ocular α-sympathomimetics. Eye cosmet-
ics, eyelid massage, changes in lid hygiene regimen, and
wearing contact lenses were prohibited during the trial.
Pregnant or breast-feeding women were excluded from
participation, as well as patients whose concurrent systemic
therapies could affect the trial parameters, who participated
in another clinical trial at the same time or were already
included in the trial, and patients with any condition which
in the investigator’s opinionwould preclude the patient from
adhering to the protocol requirements.
The primary objective of this trial was to demonstrate
superiority of 2 weeks of treatment with bibrocathol 2 % eye
ointment versus corresponding vehicle (placebo) in reduc-
ing signs and symptoms of blepharitis. The secondary
objectives were to compare further measures of efficacy,
tolerability, and safety of 2 weeks of treatment with bibro-
cathol ointment versus vehicle.
The primary efficacy parameter (assessed on V2, V3,
V4) was the sum score of four signs and symptoms of
blepharitis (severity of lid edema, lid erythema, debris,
and pouting of Meibomian glands) according to slit-lamp
examination of the worst affected eye at baseline (max-
imum 16 points in total from 0–4 points per sign/symp-
tom; higher points indicate more severe signs/symptoms).
The secondary efficacy parameters included the four sin-
gle signs/symptoms of blepharitis separately (V2, V3,
V4), antiseptic effect by palpebral smear taken from the
study eyelid on a 4-point scale (higher points indicate
more widespread growth of bacteria; assessed on V2,
V4) and subjective ocular discomfort assessed by a visual
analogue scale (VAS) ranging from 0 to 100 mm (V2,
V3, V4). For the ocular discomfort assessment, the orig-
inal ratings were transformed by mathematical rounding
rules to a scale ranging from 0 to 10 with 10 reflecting
maximum discomfort. The four grading stages mentioned
above were clearly defined for each item and could
easily be assessed by the participating physicians; they
had been developed in a previous study [6]. Bacterial
growth was assessed in local site laboratories by analy-
sis of palpebral smear, taken from the study eye lid,
with the following categories and scores: 00no growth
of bacteria; 10scattered growth of bacteria (< 7 germs);
20moderate growth (7–50 germs) and 30widespread
growth (> 50 germs).
Safety parameters consisted of a visual acuity test (per-
formed on V3 and V4), intra-ocular pressure (IOP) mea-
surement (V2, V4), change in concomitant ocular
medication (V2, V3, V4), global tolerability assessed by
the patient and the investigator on a 4-point scale with the
highest figure indicating best tolerability (V4), adverse
events (V3, V4), and vital signs examination (V3, V4).
Treatments were compared with respect to the efficacy
variables in an analysis of covariance (ANCOVA) model
with the factors of treatment and center. As baseline values
were additionally considered to have an influence on
changes from baseline, they were each included as covari-
ates in the ANCOVA model. The treatment contrast was
presented by a least squares (LS) mean for the group differ-
ence together with its 95 % confidence interval (CI) and the
p value for the presumption that the contrast is 0. Effect
sizes (Cohen’s d) were presented for group comparisons.
The absolute and relative frequencies as well as group
differences by Chi-squared tests were calculated for cate-
gorical variables. The last observation carried forward meth-
od (LOCF) for substitution of missing data was used for an
endpoint analysis in the primary and all secondary outcome
measures. In the modified intent-to-treat (ITT) population,
patients without post-baseline values for the primary effica-
cy variable were excluded from the analysis. For all other
patients, missing values of signs/symptoms were replaced
by the LOCF method (last observation carried forward).
Other missing values were not replaced. Baseline character-
istics were summarized descriptively for the ITT sample.
Safety and tolerability variables were summarized descrip-
tively for the safety sample.
The sample size estimation was based on a similar
study with bibrocathol reporting an effect size of
Cohen’s d00.43 for the difference to placebo with a
slightly different primary efficacy variable [8]. Assum-
ing that the primary efficacy measure was as sensitive
as the outcome measure of the referenced trial, 86
patients per group were required to detect such an effect
size with a power of 90 % at the two-sided significance
level of 5 %. To account for non-evaluable data due to
drop-outs, 2×1000200 patients were to be recruited for
participation in this trial.
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Results
A total number of two hundred patients was enrolled in the
trial, randomized, received bibrocathol 2 % (n0100) or pla-
cebo (n0100), and were available for safety and tolerability
analysis. Three patients were excluded from the efficacy anal-
ysis as they discontinued the study prematurely without valid
post-baseline data. Therefore, the ITT population (for demo-
graphic data see Table 1) consisted of 197 patients.
Efficacy
Baseline mean values of the sum score were very similar in
both groups (bibrocathol: 10.4 points, placebo: 10.6 points).
At V4 (LOCF) in both groups, the score was reduced (raw
values are given in Fig. 1); however, mean (± SD) reduction
from baseline was larger in the group treated with bibroca-
thol (−6.8±2.45 points) as compared to the placebo group
(−4.6±3.33 points). Difference between the treatment
groups (LS mean) was −2.32 (95 % CI: –2.84; –1.80) favor-
ing treatment with bibrocathol (p<0.0001 from ANCOVA;
Cohen’s d00.73).
Baseline means in the four sub-scores were almost equal
between the two groups. Until V4 all signs/symptoms im-
proved to a larger extent under bibrocathol than under placebo
(for raw values see Fig. 2; differences are given in Table 2).
Almost all patients had at least one ‘severe’ or ‘very
severe’ symptom in the blepharitis slit-lamp examination at
baseline (bibrocathol: 97.0 %, placebo: 97.9 %). At V4
(LOCF), only 11 patients (11.0 %) in the bibrocathol group
suffered from one such symptom. In the placebo group, still
31 (32.0 %) patients were affected with 12 patients having
more than one ‘severe’ or ‘very severe’ symptom (see Fig. 3
for frequency distribution). The group difference at V4
(LOCF) was statistically significant with p<0.001 in all four
signs/symptoms (Chi-square test).
The patients of both groups rated their subjective ocular
discomfort to be about 7.4 points on average at baseline
(100very severe). In the bibrocathol group, ocular discom-
fort improved significantly more than in the placebo group
(see Table 2). Scattered (< 7 bacteria) or moderate (8–50
bacteria) bacterial growth could be revealed at baseline in
53 % of the bibrocathol group and in 53.6 % of the placebo
group. Bacteria could no longer be identified at study end in
35.8 % of these patients under bibrocathol and in 32.7 %
under placebo.
Safety/tolerability
Visual acuity changed marginally between baseline and V4
on average (bibrocathol: 0.00±0.04 %; placebo: 0.01±
0.09 %). Only five patients (four bibrocathol, one placebo
patient) reported very small changes of vision (%). Mean
IOP was slightly reduced between baseline and V4 in both
groups (bibrocathol: –0.45±1.66; placebo: –0.34±1.78).
Tolerability of bibrocathol was reported to be ‘good’ or even
‘very good’ by almost all patients (93.0 %). Investigators’
ratings were even more favorable for bibrocathol, with
95.0 % patients classified as showing at least ‘good’ toler-
ability of bibrocathol. In the placebo group, only 47.0 % of
the patients’ and 35.0 % of the investigators’ ratings
reflected at least ‘good’ tolerability.
No patient took other ophthalmological medication than
the study medication prior to or during the study. No rele-
vant changes with regard to vital signs occurred.
Adverse events (AEs) were rare in the bibrocathol group
with six (6.0 %) patients affected by administrative site
conditions (application site pruritus in one patient and
application site reactions in the remaining five), which were
considered to be related to the study medication. The inves-
tigators reported AEs for 66 (66.0 %) placebo patients: two
patients experienced hypersensitivity against the ointment,
Table 1 Demographic data at
screening (ITT)
n number of subjects, % percent






Statistic Bibrocathol 2 % Placebo Total
n0100 n097 n0197
Age (years) M ± SD 57.3 ± 18.15 54.1 ± 17.90 55.7 ± 18.05
Median 61.0 56.0 59.0
Range 19–87 20–86 19–87
Sex
Male n (%) 42 (42.0) 45 (46.4) 87 (44.2)
Female n (%) 58 (58.0) 52 (53.6) 110 (55.8)
Ethnicity
Caucasian n (%) 99 (99.0) 97 (100) 196 (99.5)
Asian n (%) 1 (1.0) – 1 (0.5)
BMI (kg/m2) M ± SD 27.4 ± 3.58 26.6 ± 3.63 27.0 ± 3.61
Median 27.7 26.4 27.1
Range 16.6–37.1 17.5–35.4 16.6–37.1
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28 experienced application site pruritus, and 36 reported
application site reactions. Almost all AEs were mild and
lasted only for a few minutes; only two patients discontin-
ued the trial due to AEs.
Discussion
The results of this study clearly demonstrate that bibrocathol
2 % ointment was superior over vehicle ointment (placebo)
with regard to improvement of blepharitis symptoms after
2 weeks of treatment in a patient population suffering from
acute palpebral inflammation but not requiring antibiotic
treatment. As infection plays a crucial role in the etiology
of blepharitis, adding antiseptic agents to standard lid hy-
giene seems to be a reasonable and effective treatment
option, especially as it avoids the risk of bacterial resistance
and substance hypersensitivity associated with topical use of
antibiotics, at the same time decreasing the risk of side-
effects of antibiotics [1, 2, 9, 10]. Bibrocathol 2 % is an
antiseptic ointment with disinfectant, anti-inflammatory,
astringent, and secretion-inhibitory effects. Its mechanism
of action is determined by its structural components, mainly
tetrabromopyrocatechol and bismuth hydroxide. Bacterial
invasion is prevented by protein denaturation and surface
tissue diminution. In addition, the astringent effect on small
vessels reduces local inflammation and secretion [11].
Therefore, no resistance to this antiseptic agent can develop.
This mechanism of action is different from the antibac-
terial effect of antibiotics. Previous in-vitro microbiological
tests had shown a potential of an antibacterial effect (data on
file). To confirm this property in a clinical setting, palpebral
smears were taken during this study. However, these tests
could not show a relevant difference between active treat-
ment and placebo. It was concluded from these tests that the
clinical mode of action of bibrocathol 2 % is not a direct
Fig. 1 Sum score from slit-
lamp examination (ITT)
Fig. 2 Single scores from slit-
lamp examination (ITT)
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antibacterial effect comparable to antibiotic treatment. How-
ever, further evidence is needed to support the pharmacody-
namic effect of bibrocathol.
The observed treatment differences between bibrocathol
2 % and placebo are clinically relevant in the total population
and also in severely affected patients. This is indicated on the
one hand by the significant treatment differences regarding the
total score and the sub-scores with medium to large effect
sizes. In clinical trials, medium-effect sizes (d0~0.5) are
usually considered the lower limit of clinical relevance. In
Table 2 Secondary efficacy
variables; results from
ANCOVA (ITT)
n number of subjects, % percent
of subjects in each group, M
arithmetic mean, SD standard
deviation, range minimum–




Statistic Bibrocathol 2 % Placebo
n0100 n097
Edema M ± SD −1.86±0.89 −1.20±1.20
Median (range) −2.00 (−4–1) −1.00 (−4–1)
Difference LS mean (95 % CI) −0.70 (−0.88; –0.51)
p value <0.0001
Cohen’s d 0.60
Erythema M ± SD −1.77±0.85 −1.21±1.15
Median (range) −2.00 (−4–0) −1.00 (−4–0)
Difference LS mean (95 % CI) −0.57 (−0.75; –0.38)
p value <0.0001
Cohen’s d 0.54
Debris M ± SD −1.74±0.89 −1.30±0.82
Median (range) −2.00 (−4–0) −1.00 (−4–0)
Difference LS mean (95 % CI) −0.47 (−0.65; –0.29)
p value <0.0001
Cohen’s d 0.50
Pouting of Meibomian glands M ± SD −1.46±0.80 −0.90±1.08
Median (range) −1.00 (−4–0) −1.00 (−4–0)
Difference LS mean (95 % CI) −0.62 (−0.82; –0.43)
p value <0.0001
Cohen’s d 0.57
VAS (0–10) M ± SD −4.69±1.95 −2.79±2.29
Median (range) −5.00 (−10–1) −2.00 (−9–1)
Difference LS mean (95 % CI) −1.86 (−2.25; –1.46)
p value <0.0001
Cohen’s d 0.81
Fig. 3 Frequency distribution
of patients with ‘severe’ or
‘very severe’ symptoms at
baseline and last visit
(LOCF) [ITT]
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our study, the effect size was 0.73 for the primary endpoint,
which is clearly above the ‘medium’ level and close to the
requirement for a ‘large’ effect (d≥0.8). Thus, the superiority
of bibrocathol 2 % over placebo is not only statistically
significant but also clinically relevant. On the other hand,
there were very few patients with severe or very severe symp-
toms in the bibrocathol group as compared to the placebo
group although vehicle therapy also showed a curing effect
at the end of the 14-day treatment period. Additionally, by
defining a responder as a patient with a total score <4 and each
of the 4 signs/symptoms being ≤1, we found 58.0 % respond-
ers in the bibrocathol and 25.8 % responders in the placebo
group (p<0.0001 in Fisher’s exact test).
The high number of application site reactions or pruritus in
the placebo group may rather be attributable to disease symp-
toms, which did not improve under therapy than to AEs caused
by the placebo ointment, as their occurrence was associated
with a higher blepharitis total score in both groups (correlation
of ρ00.69 for the total sample). This is in accordance with our
expectation that the application of eye ointment could possibly
cause application site discomfort, which may be perceived
more intensely by patients with no or slow symptom improve-
ment than by patients with fast symptom improvement.
Taking the favorable tolerability and safety of bibrocathol
2 % eye ointment into account, together with the clinically
relevant efficacy as shown by symptom improvement, it is
concluded that the antiseptic bibrocathol 2 % is an efficacious
therapy of acute forms of blepharitis with a positive risk–
benefit ratio. In clinical practice, it can help to avoid the risks
of antibiotic treatment including bacterial resistance or hyper-
sensitivity reactions. Further clinical investigations may
include a long-term follow-up over several months, and other
trials could prove the efficacy of bibrocathol 2 % in long-term
treatment to confirm its benefits in chronic forms of blepharitis.
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